Ginkgo Bioworks Teams Up With Pfizer in $331 Million Deal to Discover New RNA Therapeutics
-
Ginkgo Bioworks announced a new collaboration with Pfizer to discover novel RNA-based drug candidates.
-
The collaboration will leverage Ginkgo's proprietary RNA technology to advance RNA molecules for priority research areas.
-
The deal is worth up to $331 million across 3 programs, including upfront payment, research fees, milestones.
-
Ginkgo's RNA platform combines screening and multi-parameter design to optimize RNA constructs.
-
RNA therapeutics are an emerging approach to treating diseases, and Ginkgo's technology aims to improve RNA drug properties.
![](https://mma.prnewswire.com/media/1583909/Ginkgo_Logo_Lockup.jpg?p=facebook)